Skip to main content
Erschienen in: gynäkologie + geburtshilfe 1/2017

14.02.2017 | Mammakarzinom | Zertifizierte Fortbildung

Vorgehen in der Prä- und Postmenopause

Adjuvante endokrine Therapie des Mammakarzinoms

verfasst von: Steffi Hartmann, Prof. Dr. Toralf Reimer, Angrit Stachs

Erschienen in: gynäkologie + geburtshilfe | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei Brustkrebspatientinnen mit Östrogen- und/oder Progesteronrezeptor-positiven Tumoren ist eine adjuvante endokrine Therapie indiziert. Neben Risikoprofil und Nebenwirkungen sollte für die Therapie der Menopausenstatus der Betroffenen Beachtung finden.
Literatur
3.
Zurück zum Zitat Hammond ME et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.CrossRefPubMedPubMedCentral Hammond ME et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ravdin RG et al. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet. 1970;131(6):1055–64. Ravdin RG et al. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet. 1970;131(6):1055–64.
6.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348(9036):1189-96. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348(9036):1189-96.
7.
Zurück zum Zitat Goldhirsch A et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.CrossRefPubMedPubMedCentral Goldhirsch A et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Partridge AH et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20.CrossRefPubMed Partridge AH et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20.CrossRefPubMed
9.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.
11.
Zurück zum Zitat Clemons M, Simmons C: Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat. 2007;104(2):115–20.CrossRefPubMed Clemons M, Simmons C: Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat. 2007;104(2):115–20.CrossRefPubMed
12.
Zurück zum Zitat Tevaarwerk AJ et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948–58.CrossRefPubMedPubMedCentral Tevaarwerk AJ et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948–58.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Francis PA et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.CrossRefPubMed Francis PA et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.CrossRefPubMed
15.
Zurück zum Zitat Gnant M et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015; 26(2):313–20.CrossRefPubMed Gnant M et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015; 26(2):313–20.CrossRefPubMed
16.
Zurück zum Zitat Ribi K et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016;34(14):1601–10.CrossRefPubMed Ribi K et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016;34(14):1601–10.CrossRefPubMed
17.
Zurück zum Zitat Kim HA et al. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. BMC Cancer. 2016;16:319.CrossRefPubMedPubMedCentral Kim HA et al. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. BMC Cancer. 2016;16:319.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Regan MM et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221–31.CrossRefPubMed Regan MM et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221–31.CrossRefPubMed
19.
Zurück zum Zitat Coates AS et al. Tailoring therapies — improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–46.CrossRefPubMedPubMedCentral Coates AS et al. Tailoring therapies — improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–46.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689–701.CrossRefPubMed Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689–701.CrossRefPubMed
21.
Zurück zum Zitat Harbeck N, Herausgeber. Zielgerichtete Therapien beim Mammakarzinom. Der Praxisguide. 1. Auflage. Stuttgart: Schattauer Verlag; 2014. Harbeck N, Herausgeber. Zielgerichtete Therapien beim Mammakarzinom. Der Praxisguide. 1. Auflage. Stuttgart: Schattauer Verlag; 2014.
22.
Zurück zum Zitat Ryden L et al. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast. 2016;26:106–14.CrossRefPubMed Ryden L et al. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast. 2016;26:106–14.CrossRefPubMed
23.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341-52. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341-52.
24.
Zurück zum Zitat O'Leary CG et al. Extended adjuvant endocrine therapy in hormone receptor-positive early breast cancer. Curr Opin Oncol. 2016;28(6):455–460.CrossRefPubMed O'Leary CG et al. Extended adjuvant endocrine therapy in hormone receptor-positive early breast cancer. Curr Opin Oncol. 2016;28(6):455–460.CrossRefPubMed
25.
Zurück zum Zitat Gray RG et al. ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31(Suppl):Abstr 5. Gray RG et al. ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31(Suppl):Abstr 5.
26.
Zurück zum Zitat Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2013;381(9869):805–16.CrossRefPubMedPubMedCentral Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2013;381(9869):805–16.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.CrossRefPubMed Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.CrossRefPubMed
28.
Zurück zum Zitat Mamounas EP et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965–71.CrossRefPubMed Mamounas EP et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965–71.CrossRefPubMed
29.
Zurück zum Zitat Jakesz R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG 6a). J Clin Oncol. 2005;23(16 Suppl):Abstr 527. Jakesz R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG 6a). J Clin Oncol. 2005;23(16 Suppl):Abstr 527.
30.
Zurück zum Zitat Zdenkowski N et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomized, controlled trial. Ann Oncol. 2016;27(5):806–12.CrossRefPubMed Zdenkowski N et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomized, controlled trial. Ann Oncol. 2016;27(5):806–12.CrossRefPubMed
31.
Zurück zum Zitat Goss PE et al. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol 2016; 34(Suppl):Abstr LBA1. Goss PE et al. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol 2016; 34(Suppl):Abstr LBA1.
32.
Zurück zum Zitat Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol. 2016;8(4):261–6.CrossRefPubMedPubMedCentral Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol. 2016;8(4):261–6.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.CrossRefPubMedPubMedCentral Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Bauerschlag DO et al. Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer. Breast Care (Basel). 2014;9(4):283–6.CrossRef Bauerschlag DO et al. Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer. Breast Care (Basel). 2014;9(4):283–6.CrossRef
35.
Zurück zum Zitat Harris LN et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134–50.CrossRefPubMedPubMedCentral Harris LN et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134–50.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Spring LM et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–1486.CrossRefPubMed Spring LM et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–1486.CrossRefPubMed
Metadaten
Titel
Vorgehen in der Prä- und Postmenopause
Adjuvante endokrine Therapie des Mammakarzinoms
verfasst von
Steffi Hartmann
Prof. Dr. Toralf Reimer
Angrit Stachs
Publikationsdatum
14.02.2017
Verlag
Springer Medizin
Erschienen in
gynäkologie + geburtshilfe / Ausgabe 1/2017
Print ISSN: 1439-3557
Elektronische ISSN: 2196-6435
DOI
https://doi.org/10.1007/s15013-017-1049-7

Weitere Artikel der Ausgabe 1/2017

gynäkologie + geburtshilfe 1/2017 Zur Ausgabe